Skip to main content

Table 2 Cancer incidence in patients with tuberculosis according to time since tuberculosis diagnosis

From: Non-pulmonary cancer risk following tuberculosis: a nationwide retrospective cohort study in Lithuania

Type of cancer

ICD-O

Time since tuberculosis diagnosis

<1 year

1–4 years

≥5 years

Total

Exp

Obs

SIR (95% CI)

Exp

Obs

SIR (95% CI)

Exp

Obs

SIR (95% CI)

Exp

Obs

SIR (95% CI)

All but NMS

C00–96, excl. C44

107.7

347

3.22 (2.89–3.58)

377.0

625

1.74 (1.60–1.88)

450.5

611

1.36 (1.25–1.47)

935.2

1583

1.76 (1.67–1.85)

All but NMS & lung

C00–96, excl. C44, C33, C34

91.6

186

2.03 (1.75–2.34)

310.9

429

1.38 (1.25–1.52)

379.6

490

1.29 (1.18–1.41)

782.1

1105

1.41 (1.33–1.50)

Mouth, pharynx

C01–14

4.3

20

4.65 (2.84–7.18)

13.8

57

4.27 (3.24–5.54)

13.9

45

3.24 (2.36–4.33)

32.0

122

3.92 (3.25–4.68)

Oesophagus

C15

2.1

9

4.28 (1.96–8.13)

7.0

28

4.22 (2.80–6.10)

7.3

26

3.57 (2.33–5.23)

16.4

63

3.99 (3.07–5.11)

Stomach

C16

7.6

16

2.11 (1.21–3.44)

24.9

30

1.28 (0.86–1.83)

27.0

45

1.67 (1.22–2.23)

59.4

91

1.60 (1.29–1.96)

Colon

C18

4.9

2

0.41 (0.05–1.47)

17.4

20

1.21 (0.74–1.87)

22.3

18

0.81 (0.48–1.27)

44.7

40

0.93 (0.67–1.27)

Rectum

C19–21

4.8

6

1.25 (0.46–2.75)

16.7

14

0.89 (0.49–1.48)

20.2

23

1.14 (0.72–1.71)

41.7

43

1.08 (0.78–1.45)

Liver

C22

1.2

3

2.47 (0.51–7.25)

4.3

9

2.20 (1.01–4.19)

5.5

9

1.63 (0.74–3.09)

11.1

21

1.98 (1.23–3.03)

Pancreas

C25

3.3

10

3.00 (1.44–5.52)

11.3

16

1.50 (0.86–2.43)

13.2

16

1.21 (0.69–1.97)

27.8

42

1.57 (1.13–2.12)

Larynx

C32

2.7

14

5.17 (2.82–8.67)

8.7

22

2.67 (1.67–4.04)

8.7

17

1.96 (1.14–3.14)

20.0

53

2.74 (2.05–3.59)

Bone, mesothelial & soft tissue

C40–41, C45, C47, C49

0.9

4

4.43 (1.21–11.40)

2.9

4

1.44 (0.39–3.68)

3.1

6

1.97 (0.72–4.28)

6.8

14

2.11 (1.15–3.54)

Melanoma

C43

1.7

1

0.58 (0.02–3.22)

6.0

3

0.51 (0.11–1.50)

7.3

3

0.41 (0.08–1.20)

15.0

7

0.48 (0.19–0.96)

Breasta

C50

5.7

3

0.53 (0.11–1.55)

20.3

15

0.74 (0.41–1.22)

25.9

32

1.21 (0.83–1.70)

51.9

50

0.96 (0.72–1.27)

Cervix uteri

C53

2.4

6

2.51 (0.92–5.44)

8.2

20

2.43 (1.48–3.75)

9.2

25

2.73 (1.77–4.03)

19.7

51

2.60 (1.93–3.42)

Corpus uteri

C54, C55

2.1

5

2.36 (0.77–5.50)

7.5

2

0.26 (0.03–0.95)

10.3

6

0.58 (0.21–1.27)

19.9

13

0.66 (0.35–1.13)

Ovary

C56

1.7

5

2.95 (0.96–6.86)

5.8

2

0.34 (0.04–1.23)

7.4

9

1.22 (0.56–2.32)

14.9

16

1.08 (0.62–1.76)

Prostate

C61

20.9

16

0.76 (0.44–1.24)

84.0

66

0.83 (0.64–1.05)

114.2

102

0.89 (0.73–1.08)

219.2

184

0.88 (0.76–1.02)

Kidney

C64

5.6

12

2.13 (1.10–3.72)

19.0

20

1.10 (0.67–1.70)

21.2

14

0.66 (0.36–1.11)

45.9

46

1.04 (0.76–1.38)

Bladder

C67

3.5

14

3.95 (2.16–6.62)

11.7

19

1.77 (1.06–2.76)

13.3

15

1.13 (0.63–1.87)

28.5

48

1.79 (1.32–2.37)

Brain, CNS

C70–72

2.1

3

1.45 (0.30–4.26)

6.8

9

1.36 (0.62–2.59)

7.3

5

0.69 (0.22–1.60)

16.1

17

1.08 (0.63–1.73)

Thyroid

C73

1.8

1

0.57 (0.01–3.15)

6.3

2

0.32 (0.04–1.16)

7.6

7

0.92 (0.37–1.90)

15.6

10

0.65 (0.31–1.19)

HL

C81

0.5

2

4.13 (0.50–14.90)

1.4

4

2.83 (0.77–7.25)

1.2

2

1.74 (0.21–6.30)

3.1

8

2.65 (1.14–5.22)

NHL & other LHT

C82–85, C88, C90, C96

3.0

8

2.71 (1.17–5.34)

10.6

15

1.46 (0.82–2.41)

13.2

11

0.84 (0.42–1.49)

26.7

34

1.31 (0.91–1.84)

Leukaemias

C91–95

2.6

3

1.16 (0.24–3.39)

8.8

18

2.14 (1.27–3.38)

10.6

20

1.90 (1.16–2.93)

22.0

41

1.94 (1.39–2.63)

Other

 

6.0

23

3.84 (2.43–5.76)

19.5

34

1.75 (1.21–2.44)

22.7

34

1.50 (1.04–2.10)

48.1

91

1.79 (1.43–2.21)

  1. Exp expected cases, Obs observed cases, SIR standardized incidence ratio, CI confidence interval, NMS non-melanoma skin, HL Hodgkin lymphoma, NHL Non-Hodgkin lymphoma, LHT lympho-, haematopoietic tissue
  2. ain women only, in men n = 0